Skip to main content

Baxter Buys Claris Injectables for $625 Million

Baxter buys generic drug maker Claris Injectables in a deal that will be accretive to earnings.

Baxter International (BAX) - Get Baxter International Inc. Report will acquire Claris Injectables for $625 million. Claris will sell Baxter its injectable generic medicines such as drugs for anesthesia and analgesics. This year Claris is expected to report revenue of $100 million. Revenue for Claris has increased by a double-digit percentage annually over the last several years as the company launched new products. The deal is expected to immediately add to Baxter's earnings. It is set to close in the second half of next year. Claris is a unit of Claris Lifesciences.

Scroll to Continue

TheStreet Recommends